Category Archives: Inside BIO Industry Analysis
The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the financial markets and the impact on public policy. Eisenberg discusses implementation of BIO’s legislative proposals and the outlook for the industry. BIO will be hosting the BIO Investor Forum to bring together industry leaders to discuss these recent developments that could have a major influence in helping to shape the future of biotechnology.
From the beginning, networking has been a central focus at BIO’s events. Our members attend our conferences primarily to seek out business opportunities and to meet other biotech executives. When company presentations were introduced at the 1998 BIO International Convention, delegates registered for the conference by mail and fax and presentations were the key means for companies to tell their stories at BIO’s early events. With BIO members asking for introductions to pharmaceutical companies, BIO Read More >
The relationship between the biotechnology and pharmaceutical industries has never been clearer – partner to survive. The Business Forum at the 2011 BIO International Convention is the world’s largest venue for partnering and it might be the best way for emerging companies to find partners . While there are many quality sources for historical deal-trends, the Campbell Alliance and BIO have created the Dealmakers’ Intentions Survey and the BIO One-on-One Partnering Forecast, two unique forward-looking, Read More >
There are now eight biotech IPOs for 2011, bringing the total for the recent US IPO window to 28. Post-IPO performance is finally picking up with the median return at +14% for these 28 IPOs. Advanced BioHealing was scheduled to IPO this week, but Shire (SHGPY) came in with a $750M offer to buy the company. Sagent Pharmaceuticals (SGNT) was the most recent IPO, back in April. Sagent is a specialty pharma company selling injectable Read More >
Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched Nasdaq Biotechnology Index (NBI). This Monday (May 23rd), six companies will be added to the Nasdaq Biotech index and two will be removed. The additions are Achillion Pharmaceuticals (ACHN), AVEO Pharmaceuticals (AVEO), Columbia Laboratories (CBRX), ISTA Pharmaceuticals (ISTA), Pacific Biosciences (PACB) and Zalicus (ZLCS). The two companies to be removed from the NBI are Biodel (BIOD) and China Sky One Read More >